Fly News Breaks for July 6, 2015
AEGR
Jul 6, 2015 | 08:36 EDT
Guggenheim analyst William Tanner downgraded Aegerion Pharmaceuticals to Sell from Neutral with a $9 price target. The stock closed Thursday at $18.59. The company's treatment for familial hypercholesterolemia, Juxtapid, has "passed its prime" with poor tolerability and the emergence of PCSK9 inhibitors, Tanner tells investors this morning in a research note.
News For AEGR From the Last 2 Days
There are no results for your query AEGR